共 50 条
- [1] DS-6000a, a novel CDH6-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical modelsANNALS OF ONCOLOGY, 2021, 32 : S363 - S364Suzuki, H.Nagase, S.Saito, C.Nagata, M.Kaneda, Y.Honda, K.Nishiya, Y.Honda, T.Nakada, T.Goto, R.Ishizaka, T.Myobatake, Y.Abe, Y.Agatsuma, T.
- [2] Antitumor Activity of a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting LGR5 in Preclinical Models of NeuroblastomaPHARMACEUTICS, 2024, 16 (07)Tu, JianghuaToh, YukimatsuAldana, Adela M.Wen, Jake J.Wu, LingJacob, JoanLi, LiPan, ShengCarmon, Kendra S.Liu, Qingyun J.
- [3] An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancerBRITISH JOURNAL OF CANCER, 2023, 128 (08) : 1592 - 1602Jacob, JoanFrancisco, Liezl E.Chatterjee, TreenaLiang, ZhengdongSubramanian, ShraddhaLiu, Qingyun J.Rowe, Julie H.Carmon, Kendra S.
- [4] DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical modelsMOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)Okajima, DaisukeYamaguchi, JunkoKitamura, MichikoKamei, ReikoMaejima, TakanoriShibutani, TomokoYasuda, SatoruToki, TadashiKaribe, TsuyoshiFujitani, TomomichiNakada, TakashiGoto, RikiNoguchi, YutakaAbe, YukiAgatsuma, Toshinori
- [5] Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer ModelsMOLECULAR CANCER THERAPEUTICS, 2024, 23 (03) : 257 - 271Suzuki, HirokazuNagase, ShotaroSaito, ChiemiTakatsuka, AtsukoNagata, MotokoHonda, KokichiKaneda, YukiNishiya, YumiHonda, TomoyoIshizaka, TomomichiNakamura, KensukeNakada, TakashiAbe, YukiAgatsuma, Toshinori
- [6] Antitumor activity of Antibody-Drug Conjugates targeting cancer-expressed EGFR in Preclinical ModelsEUROPEAN JOURNAL OF CANCER, 2022, 174 : S86 - S87Fitzgerald, D.Ho, E. C. H.Miller, E.Qiu, R.Antignani, A.
- [7] A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse EventsONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (10) : 547 - 556Schoffski, PatrickConcin, NicoleSuarez, CristinaSubbiah, VivekAndo, YuichiRuan, ShilingWagner, Joel P.Mansfield, KeithZhu, XuOriguchi, ShizukaDiDominick, SarahBialucha, Carl U.Faris, Jason E.Tran, Ben
- [8] Development of a novel antibody-drug conjugate targeting endosialin/TEM-1: potent antitumor activity in sarcomaCANCER RESEARCH, 2017, 77Sala, GianlucaIacobelli, StefanoCapone, EmilyPIccolo, EnzaSauniere, Jean-FredDouet, Vanessa Vannucci
- [9] A biparatopic HER2-targeting antibody-drug conjugate demonstrates potent antitumor activity in primary tumor models that are refractory to or ineligible for HER2-targeted therapiesCANCER RESEARCH, 2016, 76Li, J. Y.Perry, S. R.Muniz-Medina, V.Wetzel, L. K.Rebelatto, M. C.Bezabeh, B. Z.Fleming, R. L.Dimasi, N.Gao, C.Wu, H.Jenkins, D. W.Osbourn, J. K.Coats, S. R.
- [10] A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificityMABS, 2025, 17 (01)Synan, AlyssaWu, Nila C.Velazquez, RobertoGesner, ThomasLogel, ClaudeMueller, KathrinGreen, AndrewBarzaghi-Rinaudo, PatriziaSimmons, QuinceyMercan, SamueleShi, XingyiLi, XunSagar, VivekKorn, JoshuaMclaughlin, MargaretTschantz, William R.Hainzl, DominikMalamas, AnthonyHuber, ThomasCebe, RegisXie, Kathleen T.D'Alessio, Joseph A.